CKD-712, identified by its CAS number 626252-75-3, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is characterized as a small molecule with a specific structure that allows it to interact with biological targets, often related to disease pathways. The compound is typically evaluated for its efficacy, safety, and pharmacokinetic properties in preclinical and clinical studies. Its solubility, stability, and reactivity are crucial for determining its suitability for drug formulation. Additionally, CKD-712 may exhibit specific biological activities, such as inhibition or modulation of certain enzymes or receptors, which are essential for its intended therapeutic effects. As with many compounds in drug development, understanding its mechanism of action, side effects, and interactions with other substances is vital for advancing its potential use in medical applications. Further research and clinical trials are necessary to fully elucidate its characteristics and therapeutic potential.

CKD-712

626252-75-3: CKD-712, identified by its CAS number 626252-75-3, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is characterized as a small molecule with a specific structure that allows it to interact with biological targets, often related to disease pathways. The compound is typically evaluated for its efficacy, safety, and pharmacokinetic properties in preclinical and clinical studies. Its solubility, stability, and reactivity are crucial for determining its suitability for drug formulation. Additionally, CKD-712 may exhibit specific biological activities, such as inhibition or modulation of certain enzymes or receptors, which are essential for its intended therapeutic effects. As with many compounds in drug development, understanding its mechanism of action, side effects, and interactions with other substances is vital for advancing its potential use in medical applications. Further research and clinical trials are necessary to fully elucidate its characteristics and therapeutic potential.

CKD-712 inhibits NF-κB, suppresses MMP-9 and VEGF, and induces G2M arrest by downregulating cyclin A/B and CDK-1.

CAS 626252-75-3

CKD-712

CKD-712

Ref: TM-T27033